| HOME >> BIOLOGY >> TECHNOLOGY |
Three new products coming soon to Bioniche's growing line of injectable
products
LAKE FOREST, Ill., July 2 /PRNewswire/ -- Bioniche Pharma, a leading
developer and manufacturer of injectable pharmaceuticals, announced today
the acquisition of Baxter Healthcare Corporation's ENLON product line,
including:
-- ENLON(R) (edrophonium chloride injection, USP) 10 mg/mL, 15 mL vial
-- ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP)
Injection 5 mL ampule
-- ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP)
Injection, 15 mL Multi-dose Vial
Bioniche purchased the rights and certain assets related to the ENLON(R) product line from Baxter, which discontinued ENLON(R) in February 2008. Bioniche anticipates launching all three codes of ENLON(R) in October 2008.
"We are pleased to reintroduce these products, providing health care professionals with access to additional options," said Steve Thornton, CEO Bioniche Pharma.
According to IMS data, 2007 sales of ENLON(R) and ENLON-PLUS(R) totaled $2,727,000 and 307,000 units.
About ENLON(R) and ENLON-PLUS(R)
ENLON(R) is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. ENLON(R) is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.
ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP)
Injec
'/>"/>
| SOURCE Bioniche Pharma Copyright©2008 PR Newswire. All rights reserved |